Nous 209

Nouscom Raises €120 Million Series D to Carry Lynch Syndrome Cancer Interception Therapy Into Pivital Territory

Clinical-stage biotech Nouscom has closed an oversubscribed €120 million Series D financing round to fund its lead immunotherapy NOUS-209 through a global, registration-enabling clinical trial for cancer interception in Lynch Syndrome carriers. This pivotal trial aims to establish a new paradigm for preventing cancer in individuals with this inherited predisposition.